Skip to main content

Research Portfolio

Mohin is an Indian biomedical researcher with more than a decade of cumulative academic, laboratory, and translational research exposure spanning pharmacy, biotechnology, molecular biology, and clinical endocrinology. His training reflects a progressive, method-oriented trajectory developed within nationally recognized academic institutions and tertiary-care research settings in India, with sustained engagement in both experimental and clinically integrated research environments.

His formal scientific training began with a Bachelor of Pharmacy (2009–2013) at Dharmsinh Desai University, Gujarat, where he acquired a strong foundation in pharmaceutical sciences, biochemistry, pharmacology, and experimental laboratory practices. His undergraduate research focused on prebiotics and probiotics, providing early exposure to host–microbiota interactions and hypothesis-driven biological inquiry. During this period, he also served as a student coordinator for a university newsletter initiative, gaining experience in academic communication, coordination, and documentation.

He subsequently completed a M.S. (Pharm.) in Biotechnology (2015–2017) at the National Institute of Pharmaceutical Education and Research, Guwahati, an Institute of National Importance under the Government of India. His master’s thesis involved a pharmacogenomic investigation of the CYP2C19 gene in clopidogrel-treated cardiovascular disease patients using restriction fragment length polymorphism–based genotyping. This work was carried out under the mentorship of Dr. Ranadeep Gogoi as chief guide and Dr. Utpal Mohan as co-guide, with structured guidance in experimental design, molecular analysis, and interpretation of genotype–phenotype associations. During his master’s training, Mohin received extensive hands-on exposure to mammalian and bacterial cell culture, molecular cloning, nucleic acid isolation, SDS-PAGE, ELISA, western blotting, and core molecular biology workflows, establishing a solid experimental foundation in cellular and molecular biotechnology.

In 2014, Mohin worked as a Science Communicator at the Vikram A. Sarabhai Community Science Centre as part of the Science Express Biodiversity Special Phase III national outreach programme. This role involved extensive travel across more than fifty cities in India aboard a mobile science exhibition train. His responsibilities included curating and interpreting scientific exhibits for diverse audiences, conducting interactive hands-on learning activities in onboard laboratories and educational zones, facilitating platform-based demonstrations and school outreach programmes, and addressing scientific queries from the public. He also supported logistical coordination, crowd management, and media interactions, contributing to large-scale science dissemination and public engagement at a national level.

His transition into clinically oriented translational research began in 2018 when he joined the Department of Endocrinology at the Postgraduate Institute of Medical Education and Research, Chandigarh, as a Junior Research Fellow. From August 2018 to July 2019, he worked on a DST–SERB–funded project titled “Identification of Potential Epigenetic Biomarkers for Detection and Diagnosis of Primary Hyperparathyroidism.” In this role, he was responsible for executing core molecular biology techniques, including DNA and RNA isolation, agarose gel electrophoresis, western blotting, and chromatin immunoprecipitation. In parallel, he was actively involved in patient enrolment, biospecimen handling, longitudinal sample management, and structured clinical data curation for the Primary Hyperparathyroidism Registry. These activities were conducted within a regulated clinical research environment, with strict adherence to approved study protocols, ethical guidelines, and data integrity standards.

From 2019 to 2025, Mohin pursued doctoral research in Endocrinology at PGIMER, Chandigarh. His PhD research focused on studying the microRNA profile in pancreatic cancer patients with and without new-onset diabetes, with the objective of exploring mechanistic links between metabolic dysregulation and malignancy. His doctoral work involved sustained exposure to RT-PCR–based microRNA expression profiling, immunohistochemical analysis of pancreatic and islet-related markers, cytokine bead array–based flow cytometry, and integration of molecular findings with clinical, biochemical, and imaging data. His research was conducted in close collaboration with endocrinologists, pathologists, gastroenterologists, and laboratory scientists, enabling direct work with patient-derived biospecimens and registry-linked clinical datasets in a multidisciplinary tertiary-care setting.

Following his doctoral research, Mohin was appointed as Project Technical Support–III in the Department of Endocrinology at PGIMER from May to November 2025. In this role, he contributed to an ICMR-funded multicentric interventional study titled “Drug intervention for prevention of type 2 diabetes among women with prior gestational diabetes mellitus and pre-diabetes in South Asia (DIVINE).” His responsibilities included systematic patient recruitment, comprehensive clinical data management, detailed evaluation and interpretation of medical records, and screening and identification of eligible participants for gestational diabetes mellitus–related diagnoses. These activities were carried out with a strong emphasis on methodological rigor, protocol compliance, and coordinated data handling across multiple study sites.

Across his academic and research appointments, Mohin has developed documented experience in a broad range of experimental methodologies, including quantitative RT-PCR, immunohistochemistry, flow cytometry–based cytokine analysis, western blotting, ELISA, molecular cloning, chromatin immunoprecipitation, and regulated human biospecimen handling. His research practice consistently emphasizes careful sample handling, reproducible laboratory workflows, and alignment of molecular assays with clinically relevant research questions.

He has contributed as a co-author to multiple peer-reviewed publications in international journals spanning endocrinology, metabolic bone disease, and translational clinical research, reflecting sustained collaborative engagement in multidisciplinary research teams. His professional development is further supported by participation in numerous national and institutional workshops, conferences, and certified training programmes covering bioinformatics tools for genomic data analysis, flow cytometry applications, pharmacogenomics, immunobiology techniques, stem cell methodologies, organoid models for cancer research, animal models in disease, Sanger sequencing, and structured clinical case conferences.

In parallel with wet-lab research, Mohin is actively developing competency in computational and data-driven biology. He applies guided and AI-assisted workflows using R and RStudio, Python, Conda environments, and Jupyter notebooks to support data exploration, statistical analysis, visualization, and reproducible research practices alongside experimental work. His current professional focus lies at the interface of molecular biology, clinical endocrinology, cancer biology, and bioinformatics, with a method-centric approach grounded in reproducibility, interdisciplinary collaboration, and responsible scientific practice.

Comments

Popular posts from this blog

KRAS-Driven Oncogenic Signalling in Pancreatic Ductal Adenocarcinoma: Molecular Mechanisms, Regulatory Pathways, and Therapeutic Frontiers

Pancreatic ductal adenocarcinoma (PDAC) is a characteristically aggressive tumour resistant to chemotherapy, and at the centre of this malignant phenotype lies an almost universal dependency on activating mutations in the KRAS oncogene. More than 90 %of PDAC tumours present with alterations in the  KRAS oncogene, most frequently at codon 12, and these mutations represent the primary cause of the tumour’s signalling complexity, metabolic heterogeneity and stromal orchestration. The predominance of KRAS in PDAC reflects the capacity of mutant KRAS to adversely affect cellular processes in the tumour microenvironment that sustain the tumour’s growth, plasticity, survival and resistance to therapy. The biochemical behaviour of KRAS is rooted in its role as a molecular switch cycling between inactive GDP-bound and active GTP-bound conformations. In physiologically normal cells, this transition is carefully modulated by guanine nucleotide exchange factors and GTPase-activat...

From Script Usage to Computational Reasoning: My Progression in Python, R, and Bioinformatics

This article is a reflective and technical account of how my understanding and practical usage of Python , R , RStudio , and bioinformatics workflows has evolved over time. It is written deliberately without hype. The goal is not to exaggerate proficiency, but to document growth, limitations, scale of data handled, and a statistically reasoned trajectory of where my computational capacity is realistically headed over the next three years. 1. Starting Point: Computational Literacy, Not Expertise My initial engagement with programming languages was not as a formally trained computer scientist, but as a biomedical researcher responding to data pressure. Early usage of R and Python was functional and problem-driven: plotting figures, running basic statistics, reshaping tables, and automating repetitive tasks. I did not begin with algorithmic depth; I began with necessity. At this stage, my interaction with code was characterized by: Script reuse with modification Heavy reli...

HMGN5-Mediated Chromatin Remodeling as a Driver of Breast Cancer Proliferation: Epigenetic Mechanisms, Transcriptional Accessibility, and Therapeutic Implications

Abstract High Mobility Group Nucleosome-binding protein 5 (HMGN5) has emerged as an important chromatin architectural regulator involved in the epigenetic control of transcription, chromatin accessibility, and oncogenic transformation. Recent evidence demonstrates that aberrant HMGN5 expression contributes significantly to breast cancer progression through modulation of chromatin dynamics and activation of proliferation-associated transcriptional programs. HMGN5 belongs to the HMGN family of non-histone chromosomal proteins that interact directly with nucleosomes and regulate higher-order chromatin structure. Unlike sequence-specific transcription factors, HMGN proteins exert genome-wide regulatory effects by altering nucleosomal stability, histone modification accessibility, and transcriptional competency. In breast carcinoma, elevated HMGN5 expression correlates with aggressive clinical phenotypes, enhanced proliferative capacity, increased DNA replication activity, and poor prognosi...